Karmazyn M, Manku M S, Horrobin D F
Endocrinology. 1978 Apr;102(4):1230-6. doi: 10.1210/endo-102-4-1230.
Arginine vasopressin in physiological concentrations potentiated the vascular effects of various vasoconstrictor agents. By using the isolated rat mesenteric artery preparation, the pressor effects of norepinephrine, angiotensin II, and potassium chloride were all significantly increased when vasopressin was added to the perfusion buffer. Cortisol and lithium both inhibited the potentiating effect of vasopressin but had no effect on the control pressor response to norepinephrine. When the vascular effects of norepinephrine were first blocked with indomethacin and then restored by the addition of prostaglandin E2, the potentiation by vasopressin was almost completely prevented. This suggests that vasopressin may be acting by stimulating prostaglandin biosynthesis. Cortisol and lithium may exert their inhibitory effects by preventing the activation of prostaglandin synthesis by vasopressin. These findings may be of clinical significance because the phenomena occur well within the range of vasopressin levels found in human plasma.
生理浓度的精氨酸加压素可增强各种血管收缩剂的血管效应。通过使用离体大鼠肠系膜动脉标本,当向灌注缓冲液中加入加压素时,去甲肾上腺素、血管紧张素II和氯化钾的升压效应均显著增强。皮质醇和锂均抑制加压素的增强作用,但对去甲肾上腺素的对照升压反应无影响。当先用吲哚美辛阻断去甲肾上腺素的血管效应,然后通过添加前列腺素E2恢复时,加压素的增强作用几乎完全被阻止。这表明加压素可能通过刺激前列腺素生物合成起作用。皮质醇和锂可能通过阻止加压素激活前列腺素合成发挥其抑制作用。这些发现可能具有临床意义,因为这些现象在人血浆中加压素水平范围内很容易出现。